GlassScriptPhysician profile
Abby Carter
NPI 1508425844
$2,843.97
in general payments reported to CMS, 2019-2025
28 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $479 · 2023: $1,032 · 2024: $837 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Education: $21.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,984.87 |
| Education | $21.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $763.37 | 2021-2025 | |
| Janssen Biotech, INC. | $260.14 | 2022-2024 | Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.53 | 2021-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $146.06 | 2022-2024 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $136.76 | 2021-2024 | Entyvio, Eohilia |
| Merz North America, INC. | $132.30 | 2024 | |
| Ferring Pharmaceuticals INC. | $129.73 | 2021-2023 | Rebyota |
| Braintree Laboratories, INC. | $119.92 | 2021-2024 | Suflave |
| Ironwood Pharmaceuticals, INC | $110.06 | 2021-2024 | Linzess |
| Genzyme Corporation | $95.24 | 2023-2024 | |
| Ardelyx, INC. | $77.23 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $74.54 | 2023-2024 | Dupixent |
| Intercept Pharmaceuticals, INC. | $68.54 | 2021-2024 | Ocaliva |
| Novo Nordisk INC | $63.50 | 2021-2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $62.05 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $57.96 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $56.17 | 2023 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.25 | 2021-2024 | Cyltezo |
| Lilly USA, LLC | $37.17 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $36.57 | 2022-2024 | Dificid |
| Fresenius Kabi USA, LLC | $34.17 | 2023 | Idacio |
| Biohaven Pharmaceuticals, INC. | $28.58 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.20 | 2025 | Voquezna |
| Organon LLC | $23.92 | 2023-2024 | Hadlima, Renflexis |
| Albireo Pharma, INC. | $22.09 | 2024 | Bylvay |
| Celltrion USA INC. | $21.69 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $20.42 | 2021 | |
| Pfizer INC. | $13.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abby Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.